Telehealth Weight Loss
13 articles on Telehealth Weight Loss, researched and written by the Shotlee Editorial Team from primary sources.
Ozempic & Wegovy Safety: The Yale Study on Online Prescribing
A recent JAMA study reveals significant gaps in medical oversight for online GLP-1 prescriptions. Discover the risks and how to ensure safe access to weight loss medications.
7 min read
GLP-1s & Telehealth: Navigating Risks and Ensuring Safety
The booming popularity of GLP-1 medications for weight loss has coincided with a dramatic rise in telehealth services. This article delves into the benefits and significant risks of obtaining these powerful drugs online, highlighting critical safety concerns and offering guidance for patients.
6 min read
Wegovy, Zepbound & More: Hers Makes GLP-1s Accessible from $39
The journey to weight loss can be challenging, and for many, advanced medications like GLP-1 injectables offer a crucial pathway. However, their high cost often presents a significant barrier. Hers is changing this landscape by making popular GLP-1 and other weight loss treatments more accessible and affordable than ever before.
7 min read
Hims & Hers Downgrade: What It Means for GLP-1 Weight Loss Access
Bank of America cuts Hims & Hers price target as the telehealth giant pivots from compounded GLP-1s to branded alternatives. Here is what this shift means for patients.
8 min read
Hims & Hers Stock: Costly Wegovy Deal Challenges
Hims & Hers has resolved its dispute with Novo Nordisk, shifting to official weight loss drugs like Wegovy over controversial compounded GLP-1 alternatives. This brings legal clarity but slams profitability with higher costs and a cautious Q1 2026 revenue outlook of $600-625 million. With 2.5 million subscribers, can the stock rebound amid debt and investigations?
4 min read
Hims & Hers, Novo Nordisk End Lawsuit, Collaborate on Wegovy Sales
In a surprise turn, Novo Nordisk is dropping its lawsuit against Hims & Hers Health, paving the way for branded Wegovy and Ozempic sales on the telehealth platform. This follows Hims' brief plan for cheaper compounded versions and FDA warnings on shortages. Patients gain better access to approved GLP-1 medications.
5 min read
Experts on Hims & Hers' $1.15B Eucalyptus Acquisition
Hims & Hers is acquiring Australian telehealth firm Eucalyptus for $1.15 billion to fuel global growth amid U.S. regulatory scrutiny over compounded GLP-1s. Experts call it a smart diversification move that complements weight loss and wellness services. This expansion could reshape access to personalized care worldwide.
5 min read
Hims & Hers GLP-1 Pill Launch Backfires, Fuels Compounder Crackdown
Hims & Hers aimed to disrupt the GLP-1 market with a cheap oral semaglutide pill, but faced swift FDA backlash and a patent lawsuit from Novo Nordisk. The retreat highlights regulatory risks for compounders as branded supplies stabilize. This analysis reveals challenges in oral GLP-1 production and future paths for telehealth weight loss offerings.
6 min read
CoreAge Rx Named #1 GLP-1 Provider for 2026 by American Made GLP-1
American Made GLP-1 has crowned CoreAge Rx as the best GLP-1 provider for 2026, earning a stellar 4.9 out of 5 rating after reviewing over 10 U.S. telehealth platforms. The 'Editor's Choice' award highlights its FDA-approved semaglutide and tirzepatide programs with board-certified physician oversight. Patients report 10-26% body weight loss in 12 months with personalized care.
5 min read
Hims & Hers Shares Sink 16% as FDA Halts Wegovy Copycat Pill
Hims & Hers Health Inc. (HIMS) has halted sales of its copycat Wegovy weight loss pill just two days after launch, leading to a 16% plunge in shares amid FDA warnings and Novo Nordisk threats. This marks a regulatory pivot as GLP-1 shortages ease. Patients and investors should note the growing scrutiny on compounded versions of popular drugs like Wegovy.
5 min read
GLP-1 Envy Was Just the Beginning: Hims & Hers Super Bowl Ad
A Hims & Hers Super Bowl ad provocatively claims 'Rich people live longer,' selling telehealth access to GLP-1s, peptides, and testosterone like the elite. But as compounded drugs face DOJ scrutiny, is this democratizing care or risking safety? Dive into the ad, cultural envy, and expert concerns.
5 min read
Hims & Hers Scrutiny: Compounded GLP-1 Drug Risks
Hims & Hers investment narrative shifts amid legal scrutiny on compounded GLP-1 agonists. A January 2026 antitrust lawsuit accuses Eli Lilly and Novo Nordisk of blocking compounded Mounjaro and Wegovy. This raises uncertainties for telehealth providers reliant on these affordable weight management options.
2 min read
Rising Concerns Over Telehealth Weight Loss Programs
Health experts are expressing significant alarms over the promotion of virtual weight loss initiatives to those in fragile states. Advocacy organizations highlight indirect drug recommendations lacking adequate safeguards. Telehealth providers defend their practices while critics push for better regulation.
3 min read